Our immunohistochemical analysis revealed that 100% of RCC samples were positive for Oct-4, 98% were positive for NANOG, 31.6% for OCT4-nuclearhigh/NANOG-nuclearhigh, and 47.6% were OCT4-nuclearhigh/NANOG cytoplasmichigh phenotypes. This evidence concerns the gene POU5F1 and renal cell carcinoma.